Bagsværd, Denmark, 8 February 2018 - Novo Nordisk A/S has filed its Annual Report 2017 on Form 20-F for the financial year 2017 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2017. The reports are available at the SEC's website, www.sec.gov (http://www.sec.gov/index.htm), as well as on novonordisk.com (http://www.novonordisk.com/annualreport).
Further information
Media: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com (mailto:krsp@novonordisk.com) |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com (mailto:mailtokiau@novonordisk.com) |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com (mailto:phak@novonordisk.com) |
Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com (mailto:haoe@novonordisk.com) |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com (mailto:armk@novonordisk.com) |
Christina Kjær | +45 3079 3009 | cnje@novonordisk.com (mailto:cnje@novonordisk.com) |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com (mailto:kpvj@novonordisk.com) |
PR180208_filing of Annual Report_SEC_UK (http://hugin.info/2013/R/2167388/834349.pdf)
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire